February 2017 Vol 10, No 1

The Dream of Value-Based Care

David B. Nash, MD, MBA

Comparing Healthcare Costs Associated with Oral and Subcutaneous Methotrexate or Biologic Therapy for Rheumatoid Arthritis in the United States

Joseph Lee, PhD, Ryan Pelkey, MS, Julieanna Gubitosa, BS, Michael F. Henrick, MBA, Michael L. Ganz, PhD

Stakeholder Perspective

Identifying the Most Clinically and Economically Effective Therapies for Rheumatoid Arthritis Remains a Challenge for Providers and Payers

by Gary Branning, MBA

Sociodemographic Determinants of Out-of-Pocket Expenditures for Patients Using Prescription Drugs for Rheumatoid Arthritis

Kumar Mukherjee, PhD, Khalid M. Kamal, PhD

Stakeholder Perspective

Understanding Patients’ Demographics Is Key to Improving Clinical and Economic Healthcare Outcomes

by F. Randy Vogenberg, PhD, FASHP

Pharmaceutical Patent Litigation and the Emerging Biosimilars: A Conversation with Kevin M. Nelson, JD

Stanton R. Mehr

Biologic Disease-Modifying Antirheumatic Drugs in a National, Privately Insured Population: Utilization, Expenditures, and Price Trends

Christopher B. Atzinger, MS, PhD candidate, Jeff J. Guo, BPharm, PhD

Stakeholder Perspective

Rheumatoid Arthritis, Biologic Drugs, and Associated Cost

by Byron C. Scott, MD, MBA

Industry Trends

Top 10 Healthcare Market Trends in 2017

John Santilli, MBA, F. Randy Vogenberg, PhD, FASHP

Results 1 - 6 of 6

Copyright © Engage Healthcare Communications, LLC. All rights reserved.